{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Autistic+Disorder+in+Children+and+Adolescents",
    "query": {
      "condition": "Autistic Disorder in Children and Adolescents"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 95,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Autistic+Disorder+in+Children+and+Adolescents&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T02:57:57.174Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06577623",
      "title": "In-Person Mindfulness-based Intervention for Adolescents With Autism Spectrum Disorder and Their Caregivers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Autism"
      ],
      "interventions": [
        {
          "name": "MINDful TIME",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Southwest Autism Research & Resource Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "13 Years to 18 Years"
      },
      "enrollment_count": 28,
      "start_date": "2024-08-14",
      "completion_date": "2026-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-05-22T02:57:57.174Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06577623"
    },
    {
      "nct_id": "NCT00498173",
      "title": "Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Autism"
      ],
      "interventions": [
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "5 Years to 15 Years"
      },
      "enrollment_count": 60,
      "start_date": "2007-07",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-05-22T02:57:57.174Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Lexington, Massachusetts",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lexington",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00498173"
    },
    {
      "nct_id": "NCT04174365",
      "title": "Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Irritability Associated With Autism Spectrum Disorder (ASD)"
      ],
      "interventions": [
        {
          "name": "Brexpiprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 119,
      "start_date": "2019-10-30",
      "completion_date": "2022-09-09",
      "has_results": true,
      "last_update_posted_date": "2025-08-28",
      "last_synced_at": "2026-05-22T02:57:57.174Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04174365"
    },
    {
      "nct_id": "NCT07420478",
      "title": "TF-CBT for Autistic Youth Pilot Implementation - Open Pilot",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "PTSD and Trauma-related Symptoms",
        "Autism",
        "Trauma and Stressor Related Disorders",
        "Mental Health Services"
      ],
      "interventions": [
        {
          "name": "Trauma-Focused Cognitive Behavioral Therapy, modified for autistic youth",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-05-05",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T02:57:57.174Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07420478"
    },
    {
      "nct_id": "NCT05555615",
      "title": "Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Irritability Associated With Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Pimavanserin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ACADIA Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "5 Years to 18 Years"
      },
      "enrollment_count": 209,
      "start_date": "2022-11-02",
      "completion_date": "2025-02-14",
      "has_results": true,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-05-22T02:57:57.174Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Glendale, California • San Rafael, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "San Rafael",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05555615"
    },
    {
      "nct_id": "NCT01945957",
      "title": "Brain Imaging of Intranasal Oxytocin Treatment in Autism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autism Spectrum Disorders"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 33,
      "start_date": "2014-09",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2017-04-25",
      "last_synced_at": "2026-05-22T02:57:57.174Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01945957"
    },
    {
      "nct_id": "NCT01525901",
      "title": "Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "22q13 Deletion Syndrome",
        "Phelan-McDermid Syndrome"
      ],
      "interventions": [
        {
          "name": "Insulin-Like Growth Factor-1 (IGF-1)",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "5 Years to 12 Years"
      },
      "enrollment_count": 19,
      "start_date": "2012-02",
      "completion_date": "2016-08-23",
      "has_results": true,
      "last_update_posted_date": "2022-05-12",
      "last_synced_at": "2026-05-22T02:57:57.174Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525901"
    },
    {
      "nct_id": "NCT04569058",
      "title": "Transcranial Photobiomodulation Therapy for the Treatment of Autistic Traits in Children and Adolescents With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism",
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Transcranial Photobiomodulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "9 Years to 17 Years"
      },
      "enrollment_count": 38,
      "start_date": "2021-01-14",
      "completion_date": "2024-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-05-22T02:57:57.174Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04569058"
    },
    {
      "nct_id": "NCT07091279",
      "title": "Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Challenging Behaviour",
        "Aggression",
        "Severe Disruptive Behaviour Disorders",
        "Self-injury"
      ],
      "interventions": [
        {
          "name": "Propranolol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeremy Veenstra-vanderweele",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-01-30",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-05-22T02:57:57.174Z",
      "location_count": 2,
      "location_summary": "Staten Island, New York • White Plains, New York",
      "locations": [
        {
          "city": "Staten Island",
          "state": "New York"
        },
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07091279"
    },
    {
      "nct_id": "NCT02901431",
      "title": "A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "RO5285119",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 339,
      "start_date": "2016-11-21",
      "completion_date": "2020-06-30",
      "has_results": true,
      "last_update_posted_date": "2021-02-08",
      "last_synced_at": "2026-05-22T02:57:57.174Z",
      "location_count": 45,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Orange, California + 41 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02901431"
    }
  ]
}